Companies: 10,795·Total market cap: $144.5T
AbCellera Biologics Inc.

AbCellera Biologics Inc.

ABCLNASDAQHealthcare● Active
$5.62
$-0.75(-11.77%)
Market Cap$1.7B
P/E Ratio—
52W High$6.79
52W Low$2.33
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

AbCellera Biologics Inc. (ABCL) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001703057 · ABCL · NASDAQ · as of Jun 8, 2026

Filing snapshot

299
Total Filings
8-K
Latest Form
2026-06-05
Most Recent
2020
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001703057 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-24
Fiscal Year End
Feb 24, 2026
Accession No.
0001703057-26-000012
Primary Document
abcl-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001703057 · Accession 0001703057-26-000012

Latest Key Filings

6-KQuarterly Report

No recent filings

8-KCurrent Report
8-K
2026-06-05Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-06-05
View
10-QQuarterly Report
10-Q
2026-05-11
View
8-KCurrent Report
8-K
2026-05-11
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-07
View
ARSARS
ARS
2026-04-29
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-29
View
DEF 14AProxy Statement
DEF 14A
2026-04-29
View
S-8Employee Stock Plan Registration
S-8
2026-02-24
View
10-KAnnual Report
10-K
2026-02-24
View
8-KCurrent Report
8-K
2026-02-24
View
8-KCurrent Report
8-K
2026-01-14
View
3Initial Statement of Beneficial Ownership
FORM 3
2025-12-19
View
8-KCurrent Report
8-K
2025-12-18
View
8-KCurrent Report
8-K
2025-11-28
View
8-KCurrent Report
8-K
2025-11-12
View
Showing 1–15 of 187 filingsForm 4 / 144 hidden· 299 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001703057  |  Exchange: NASDAQ · Healthcare

AbCellera Biologics Inc. (NASDAQ: ABCL) has submitted 299 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001703057, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is AbCellera Biologics Inc.'s most comprehensive regulatory disclosure. The most recent AbCellera Biologics Inc. 10-K was filed on 2026-02-24 for fiscal year ending 2026. Historical ABCL 10-K annual reports are available from 2017 through 2026.

Investors researching AbCellera Biologics Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
SYRE SEC Filings →VERA SEC Filings →PHVS SEC Filings →CLDX SEC Filings →IMNM SEC Filings →NUVB SEC Filings →SION SEC Filings →BHVN SEC Filings →
→ ABCL Financials→ ABCL Earnings→ ABCL Insider Trades

Frequently Asked Questions

ABCL SEC Filings · 8 questions

AbCellera Biologics Inc. (ABCL) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 299 filings and access original documents at no cost. AbCellera Biologics Inc.'s CIK is 0001703057.

ABCL SEC filingsAbCellera Biologics Inc. SEC documentsfind ABCL 10-K